Addressing the Challenges in Downstream Processing Today and Tomorrow - Newer classes of biotherapies will require innovations in processing technology. - BioPharm International

ADVERTISEMENT

Addressing the Challenges in Downstream Processing Today and Tomorrow
Newer classes of biotherapies will require innovations in processing technology.


BioPharm International Supplements
Volume 24, Issue 4, pp. s8-s15

ANTIBODY-DRUG CONJUGATES

Numerous antibody drug conjugates (ADCs) are in clinical trials with most of them being used in cancer treatment with a toxin payload (26). The major downstream challenge is separation of multiple species containing different levels of the attached drug to the mAb. This results from the limited specificity for chemical conjugation of the drug to either exposed lysines or cysteines (generated by limited reduction) on the mAb. To enable straightforward downstream processing of ADCs, two main strategies have been used to generate more homogeneous molecules. These are the incorporation of additional free cysteines that can then be chemically targeted specifically or to mutate out some of the native cysteines to serines so that they are less available for coupling after a limited reduction reaction (27, 28).

mAB FRAGMENTS AND SINGLE DOMAIN mAbs

One approach to generate smaller and simpler BioTx for downstream processing is to replace full-length mAbs with antibody fragments such as single-chain variable fragments (scFvs) and antigen-binding fragments (Fabs). Cimzia and Lucentis are two recently approved Fabs produced in E. coli (29) and although no scFv has yet received regulatory approved, there are a large number of both types of Ab fragments in clinical trials (30–32). Purification of these Ab fragments utilizes normal chromatographic procedures unless the H-chain is from the VH3 IgG gene family in which case it will bind to protein A. After purification these small fragments are usually modified to improve their pharmacokinetics using technologies, such as PEGylation. PEGylation dramatically changes the chromatographic properties of proteins such that loading capacity is severely compromised thus requiring larger columns (33, 34). Additionally PEGylation can dramatically increase the viscosity of concentrated drug substances.

In addition to mAb fragments, another approach to obtain smaller less complex antibody molecules is to use either Domain Abs (human derived) or nanobodies (Llama derived), which are composed of a single variable domain of ~ 14kDa. These small single domain antibodies can be easily captured from fermentation broth using Protein A since they can be derived from the VH3 IgG gene family (35, 36). Subsequent downstream purification has been accomplished using standard chromatographic techniques (36).

VIRAL VECTORS

Using viral vectors as BioTx for gene therapy offers many exciting opportunities to inactivate new targets. Their production presents numerous challenges because of the complex nature of their composition and large size (2–5 x 106 kDa). They are usually composed of multiple proteins that encapsulate the nucleic acid payload. Additionally, there may be empty capsids that do not contain the gene of interest but are similar in physicochemical properties and can be difficult to separate from the desired product. CsCl density gradient centrifugation has long been the method of choice for their isolation; however, for clinical testing, larger scale production has recently been accomplished using standard column chromatographic methods. However, because of their large size, their binding capacity is usually very low and chromatographic media with normal pore sizes used for proteins offer no advantages since the pores are not available. Smaller beads with more surface area is the most effective manner to increase capacity (37,38). Other processes that are being utilized include tangential flow filtration that takes advantage of the large particle size for separation from smaller cellular contaminants.

VACCINES

Vaccines can be produced using numerous technologies and have been generated against proteins, polysaccharide, and small molecule targets. Pneumonia is the largest single infectious disease causing infant mortality (39). To date, three vaccines have been licensed for treating diseases caused by pneumococcus-containing polysaccharides conjugated to proteins (40).

Because prophylactic vaccines are given to a large healthy population ranging from infants to the elderly, the regulatory requirements during development and for licensure tend to be more stringent as compared with other biotherapeutic products. This also results in more early investment and upfront development work for a vaccine candidate than for a model biotherapeutic agent. Most commercial prophylactic vaccines are not well-characterized biologicals from a regulatory perspective because of their inherent complexity and/or poorly understood mechanism of action. In addition, if an in vivo animal potency model is available, the results don't usually predict the human response to the product with regards to the protein structure-immunogenecity/antigencity relationship. These reasons force sponsors to initiate extensive process characterization studies and to lock the production processes early in the clinical development program (41).

One new approach to generate vaccines is to use virus–like particles (VLP) as potent immunostimulaters with covalent attachment of many copies of the desired antigen to their surface (42). Similar to viral vectors, VLPs present unique challenges because of their large size (2.5 x106 kDa). Q (14 kDa) is the most commonly used VLP. It is derived from the structural coat protein of this virus and it naturally assembles into 180 copies of itself during expression in the cytoplasm of E. coli. Subsequent purification is accomplished by classical column chromatography techniques with size-exclusion chromatography cited most frequently, which is not a desired step for scale-up (41). The challenges to develop alternative process steps are similar to the viral vector BioTx because of low capacity for most resins as well as the fact that there may be heterogeneous levels of antigen attached to the VLPs. Another new approach is the delivery of plasmid DNA to cells, which leads to the transcription of antigens and a subsequent immune response (43).

An additional complexity is the fact that many vaccines are multivalent. The manufacturing processes for these vaccines involve many different fermentation, purification, and conjugation trains for the polysaccharides and carrier proteins. Developing processes that are similar between antigens can improve manufacturability and facility fit (44).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here